


**REMARKS**

The Applicants elect Group IV, Claims 1, 17-25, 32, and 39-42, with traverse. Upon amendment, Claims 1, 17-25, and 39-42 are readable thereon. Claim 32 is duplicative of Claim 19; the Applicants do not waive any rights to the subject matter of Claim 32 by this amendment.

The Applicants urge that all species should be considered in this case because the searches would substantially overlap. All species fall within the same patent classification, all would involve the same search terms, and many actual references concern more than one species. Together, these factors show that no undue burden of search is imposed by considering all of the identified species together.

**Conclusion.** In light of the foregoing amendments and remarks, the Applicants respectfully request entry of this restriction, removal of all requirements, and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: March 22, 2002

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

VERSION WITH MARKINGS TO SHOW CHANGES MADE

39. The method of any of claims 17 to 3825, wherein the condition treated is rheumatoid arthritis.

40. The method of any of claims 17 to 3825, wherein the condition treated is multiple sclerosis.

41. The method of any of claims 17 to 3825, wherein the condition treated is osteoporosis.

42. The method of any of claims 17 to 3825, wherein the condition treated is osteomyelitis.